SCHEMBL9540147

SCHEMBL9540147

C#CC1(c2ccccc2)c2cc(N)ccc2NC(=O)N1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.37
AKR1B1 P15121 12/20 0.35
FSHR P23945 1/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
CHEK1 O14757 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
RET P07949 1/20 0.33
MET P08581 1/20 0.33
PDGFRA P16234 1/20 0.33
FLT1 P17948 1/20 0.33
LTK P29376 1/20 0.33
PRKX P51817 1/20 0.33
NEK2 P51955 1/20 0.33
JAK3 P52333 1/20 0.33
BTK Q06187 1/20 0.33
MAP4K2 Q12851 1/20 0.33
DYRK1A Q13627 1/20 0.33
TAOK1 Q7L7X3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9539767 0.85 AKR1B1 (0.48) BRD4AKR1B1
SCHEMBL9539078 0.85 AKR1B1 (0.48) BRD4AKR1B1PKMBACE1
SCHEMBL9542879 0.84 AKR1B1 (0.46) BRD4AKR1B1PKM
SCHEMBL9539832 0.81 AKR1B1 (0.51) BRD4AKR1B1NR1H2NR1H3
SCHEMBL9540059 0.71 PGR (0.40) AKR1B1
SCHEMBL9542678 0.70 AKR1B1 (0.38) AKR1B1
SCHEMBL9539751 0.69 AKR1B1 (0.38) AKR1B1
SCHEMBL9538989 0.68 AKR1B1 (0.44) AKR1B1
SCHEMBL9540206 0.67 AKR1B1 (0.33) AKR1B1
SCHEMBL9540131 0.66 AKR1B1 (0.44) AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0530994-A1 Quinazoline derivatives as inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1993-03-10 EP disclosed
WO-1993004047-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE MERCK & CO., INC. (US) 1993-03-04 WO disclosed